

Innovation in Breast Cancer

iBC 2024

15th - 16th Feb
2024
VIRTUAL **FORMAT**



Peter Schmid

Barts Cancer Institute, London, UK

Professor of Cancer Medicine; Centre Lead, Centre of Experimental Cancer Medicine; Director, Barts Breast Cancer Centre

My research interests focus on improving the care of women with breast cancer through clinical trials. I lead a spectrum of clinical studies spanning the spectrum of the disease and ranging from phase I to randomised phase III. The majority of these studies are translational phase II studies investigating novel targeted and immune therapies. Our current interests include cancer immune therapy combinations across all stages and subtypes of breast cancer, novel targeted agents and antibody-drug conjugates - alone or in combination - to overcome resistance, and innovative biomarker-driven trial concepts (including a preoperative window of opportunity platform to evaluate novel immunotherapy combinations in breast cancer).

Other Activities

Clinical director, Barts Breast Cancer Centre, St Bartholomew's Hospital

Chair, European Society for Medical Oncology (ESMO) breast cancer faculty

Scientific committee/faculty for the major global oncology meetings

ECMC strategy group and ECMC Intelligence Steering Committee

Clinical Expert for the UK National Institute for Health and Clinical Excellence (NICE), nominated by the Royal College of Physicians

International guidelines for breast cancer

Major Funding

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with TNBC (CI). Roche, 2018-2022

ECLIPSE: A phase II trial investigating preoperative combination strategies for immunotherapy in patients with operable, ER-positive, HER2-negative primary breast cancer (CI). Roche, 2017-2022

Barts Experimental Cancer Medicine Centre (PI). Cancer Research UK and NIHR. 2017-2022, £2M

Comprehensive Analysis of Circulating Biomarkers in breast cancer patients (CI). Barts Charity, 2015-2022, £499,652

ARB-ER - Randomized Phase II window study of short-term preoperative treatment with enzalutamide plus exemestane versus exemestane in ER-positive breast cancer (CI). Astellas, 2014-2017

ARB-TNBC - Phase II window study of short-term preoperative treatment with enzalutamide in patients with triple negative breast cancer (CI). Astellas, 2014-2017

MANTA - Randomized Phase II study of Fulvestrant in combination with AZD2014 or Everolimus or Fulvestrant alone in ER-positive metastatic breast cancer (CI). Astra Zeneca, 2013-2018

CRUKE/12/051: PAKT - Phase II, randomized, placebo-controlled study of paclitaxel +/- the AKT inhibitor AZD5363 in triple-negative breast cancer (CI). CRUK/Astra Zeneca, 2013-2018